GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zymeworks Inc (NAS:ZYME) » Definitions » PB Ratio

Zymeworks (Zymeworks) PB Ratio

: 1.34 (As of Today)
View and export this data going back to 2017. Start your Free Trial

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-19), Zymeworks's share price is $8.85. Zymeworks's Book Value per Share for the quarter that ended in Dec. 2023 was $6.63. Hence, Zymeworks's PB Ratio of today is 1.34.

The historical rank and industry rank for Zymeworks's PB Ratio or its related term are showing as below:

ZYME' s PB Ratio Range Over the Past 10 Years
Min: 0.96   Med: 2.69   Max: 7.91
Current: 1.33

During the past 10 years, Zymeworks's highest PB Ratio was 7.91. The lowest was 0.96. And the median was 2.69.

ZYME's PB Ratio is ranked better than
72.26% of 1312 companies
in the Biotechnology industry
Industry Median: 2.385 vs ZYME: 1.33

During the past 12 months, Zymeworks's average Book Value Per Share Growth Rate was -15.20% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -9.40% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 2.90% per year.

During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Zymeworks was 138.60% per year. The lowest was -9.40% per year. And the median was 16.40% per year.

Back to Basics: PB Ratio


Zymeworks PB Ratio Historical Data

The historical data trend for Zymeworks's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zymeworks Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.32 5.31 3.07 1.01 1.57

Zymeworks Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.01 1.22 1.30 1.01 1.57

Competitive Comparison

For the Biotechnology subindustry, Zymeworks's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zymeworks PB Ratio Distribution

For the Biotechnology industry and Healthcare sector, Zymeworks's PB Ratio distribution charts can be found below:

* The bar in red indicates where Zymeworks's PB Ratio falls into.



Zymeworks PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Zymeworks's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=8.85/6.629
=1.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Zymeworks  (NAS:ZYME) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Zymeworks PB Ratio Related Terms

Thank you for viewing the detailed overview of Zymeworks's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Zymeworks (Zymeworks) Business Description

Traded in Other Exchanges
Address
108 Patriot Drive, Suite A, Middletown, DE, USA, 19709
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Executives
Paul Andrew Moore officer: Chief Scientific Officer 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4
Christopher Astle officer: SVP & Chief Financial Officer 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4
Kenneth Galbraith director, officer: Chair & CEO OCEAN PARK RPO PO BOX 45025, 12851 16TH AVE, SURREY A1 V4A9L1
Carlos Campoy director 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Miller Derek John Michael director 108 PATRIOT DRIVE, SUITE A, 1385 WEST 8TH AVENUE, SUITE 540, MIDDLETOWN DE 19709
Neil A Klompas officer: President & COO 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4
Lota S. Zoth director 334 CR 692, BUFFALO GAP TX 79508
Troy Cox director C/O FOUNDATION MEDICINE, INC., C/O FOUNDATION MEDICINE, INC., 150 SECON, CAMBRIDGE MA 02141
Kenneth J. Hillan director C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Hollings Renton director
Kelvin Neu director 860 WASHINGTON STREET, 10TH FLOOR, NEW YORK NY 10014
Natalie Sacks director C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
Susan Mahony director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Neil Josephson officer: Chief Medical Officer 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4